Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique

Advances in Therapy

Volumn 32, Issue 10, 2015, Pages 929-943

  Maher, Toby M ^a   Whyte, Moira K B ^b   Hoyles, Rachel K ^c   Parfrey, Helen ^d   Ochiai, Yuuki ^e   Mathieson, Nicky ^e   Turnbull, Alice ^f   Williamson, Nicola ^g   Bennett, Bryan M ^g  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d PAPWORTH HOSPITAL   (United Kingdom)

^e BOEHRINGER INGELHEIM LTD   (United Kingdom)

^f Navigant Consulting Ltd   (United Kingdom)

^g ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Acute exacerbations; Acute lung injury; Best practice; Consensus statement; Definition; Diagnosis; Idiopathic pulmonary fibrosis; Interstitial lung disease; Qualitative research; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; POLYMYXIN B; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CONSENSUS; DELPHI STUDY; DISEASE EXACERBATION; FIBROSING ALVEOLITIS; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; PHYSICIAN; TREATMENT PLANNING; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

CONSENSUS; DELPHI TECHNIQUE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PATIENT DISCHARGE; PRACTICE GUIDELINES AS TOPIC;

EID: 84946489280     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0249-6     Document Type: Article

References (52)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161((2 Pt 1)):646–64.
2. American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
3. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med. 2006;27(1):11–6.
4. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 2008;19(4):227–35.
5. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199–203.
6. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164(9):1722–7.
7. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213–7.
8. Fell CD. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. Clin Chest Med. 2012;33(1):51–7.
9. Ryu JH, Colby TV, Hartman TE, editors. Idiopathic pulmonary fibrosis: current concepts. Mayo Clinic Proceedings. Elsevier; 1998.
10. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–51.
11. Du Bois R. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov. 2010;9(2):129–40.
12. García-Sancho C, Buendía-Roldán I, Fernández-Plata M, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011;105(12):1902.
13. Ryu JH, Moua T, Daniels CE, et al., editors. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clinic Proceedings. Elsevier; 2014.
14. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–5.
15. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
16. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3(8):5.
17. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.
18. Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis. Clin Chest Med. 2012;33(1):59–68.
19. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103(6):1808–12.
20. Kondo A, Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: Harasawa M, Fukuchi Y, Morinari H, editors. Interstitial pneumonia of unknown etiology. Tokyo: University of Tokyo Press; 1989.
21. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002;19(5):794–6.
22. Raghu G, Chang J. Idiopathic pulmonary fibrosis: current trends in management. Clin Chest Med. 2004;25(4):621–36.
23. Collard HR, Loyd JE, King TE Jr, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007;101(9):2011–6.
24. Collard H, Yow E, Richeldi L, Anstrom K, Glazer C, investigators ftI. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14(1):73.
25. Jones J, Hunter D. Qualitative research: consensus methods for medical and health services research. BMJ (Clin Res Ed). 1995;311(7001):376–80.
26. Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476–81.
27. Powell BJ, McMillen JC, Proctor EK, et al. A compilation of strategies for implementing clinical innovations in health and mental health. Med Care Res Rev. 2012;69(2):123–57.
28. Ilic D, Nordin RB, Glasziou P, Tilson JK, Villanueva E. Development and validation of the ACE tool: assessing medical trainees’ competency in evidence based medicine. BMC Med Educ. 2014;14(1):114.
29. Rosier PF, De Ridder D, Meijlink J, Webb R, Whitmore K, Drake MJ. Developing evidence-based standards for diagnosis and management of lower urinary tract or pelvic floor dysfunction. Neurourol Urodyn. 2012;31(5):621–4.
30. Dimitrow MS, Airaksinen MS, Kivelä SL, Lyles A, Leikola SN. Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review. J Am Geriatr Soc. 2011;59(8):1521–30.
31. Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52(11):2133–8.
32. Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182(3):298–306.
33. Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1–8.
34. Linstone HA, Turoff M. The Delphi method: techniques and applications. Reading, MA: Addison-Wesley; 1975.
35. Clement S, Jarrett M, Henderson C, Thornicroft G. Messages to use in population-level campaigns to reduce mental health-related stigma: consensus development study. Epidemiol Psichiatr Soc. 2010;19(1):72–9.
36. Abe S, Seo Y, Hayashi H, et al. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Blood Purif. 2010;29(4):321–6.
37. Abe S, Azuma A, Mukae H, et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012;51(12):1487–91.
38. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J J Can Thorac Soc. 2004;11(2):117–22.
39. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–7.
40. Cerri S, Spagnolo P, Luppi F, Richeldi L. Management of idiopathic pulmonary fibrosis. Clin Chest Med. 2012;33(1):85–94.
41. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–43.
42. Horita N, Akahane M, Okada Y, et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Inter Med (Tokyo, Japan). 2010;50(3):189–95.
43. Lynch JP, Saggar R, Weigt SS, Zisman DA, White ES, editors. Usual interstitial pneumonia. Seminars in respiratory and critical care medicine; 2006: Copyright© 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
44. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.
45. Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med (Tokyo, Japan). 2009;49(2):109–15.
46. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–63.
47. Delbecq AL, Van De Ven AH. A group process model for problem identification and program planning. J Appl Behav Sci. 1971;7(4):466–92.
48. Murphy M, Black N, Lamping D, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess (Winch, Engl). 1998;2(3):i.
49. Murphy M, Black N, Lamping D, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess (Winch, Engl). 1997;2(3):i–iv (1–88).
50. Society BT. BTS guidelines for home oxygen use in adults. J Br Thorac Soc. 2015;70(1):i1–43.
51. Sackman H. Delphi critque. Lexington: Lexington Books; 1975.
52. Goodman CM. The Delphi technique: a critique. J Adv Nurs. 1987;12(6):729–34.